Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III RO7790121 in Moderately to Severely Active Crohn's Disease
jRCT2041250054Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing RO7790121 with Placebo (2 arms). Started Sep 2025; status: recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2041250054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250054.